Lotus Pharmaceutical Co Stock Book Value Per Share
| 1795 Stock | TWD 279.50 3.50 1.24% |
Lotus Pharmaceutical Co fundamentals help investors to digest information that contributes to Lotus Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Lotus Stock. The fundamental analysis module provides a way to measure Lotus Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lotus Pharmaceutical stock.
Lotus |
Lotus Pharmaceutical Co Company Book Value Per Share Analysis
Lotus Pharmaceutical's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Lotus Pharmaceutical Book Value Per Share | 51.30 X |
Most of Lotus Pharmaceutical's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lotus Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
In accordance with the recently published financial statements, the book value per share of Lotus Pharmaceutical Co is about 51 times. This is 3117.59% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The book value per share for all Taiwan stocks is 97.34% higher than that of the company.
Lotus Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lotus Pharmaceutical's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lotus Pharmaceutical could also be used in its relative valuation, which is a method of valuing Lotus Pharmaceutical by comparing valuation metrics of similar companies.Lotus Pharmaceutical is currently under evaluation in book value per share category among its peers.
Lotus Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 73.53 B | |||
| Shares Outstanding | 262.04 M | |||
| Shares Owned By Insiders | 61.63 % | |||
| Shares Owned By Institutions | 10.54 % | |||
| Price To Earning | 16.94 X | |||
| Price To Book | 4.97 X | |||
| Price To Sales | 4.31 X | |||
| Revenue | 12.65 B | |||
| Gross Profit | 5.64 B | |||
| EBITDA | 2.93 B | |||
| Net Income | 1.4 B | |||
| Cash And Equivalents | 1.97 B | |||
| Cash Per Share | 8.02 X | |||
| Total Debt | 4.67 B | |||
| Debt To Equity | 0.82 % | |||
| Current Ratio | 1.93 X | |||
| Book Value Per Share | 51.30 X | |||
| Cash Flow From Operations | 119.66 M | |||
| Earnings Per Share | 11.86 X | |||
| Target Price | 297.67 | |||
| Number Of Employees | 10 | |||
| Beta | 0.72 | |||
| Market Capitalization | 70.1 B | |||
| Total Asset | 21.22 B | |||
| Z Score | 9.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 21.22 B | |||
| Last Dividend Paid | 1.93 |
About Lotus Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lotus Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lotus Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lotus Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lotus Stock Analysis
When running Lotus Pharmaceutical's price analysis, check to measure Lotus Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lotus Pharmaceutical is operating at the current time. Most of Lotus Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Lotus Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lotus Pharmaceutical's price. Additionally, you may evaluate how the addition of Lotus Pharmaceutical to your portfolios can decrease your overall portfolio volatility.